Skip to content
Screener

Cytokinetics CYTK Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$19.4MBeat by $10.8M
EPS-$1.67In line
Revenue estimate$8.5M
EPS estimate-$1.67

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$39.9M
EPS estimate-$1.45

Financials

Q1 2026

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$8.12B+70.6%
Enterprise value$8.41B+70.7%
P/S76.7×-171×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Current ratio4.2×-1.8×

Segments

By product

See full
License And Milestone Revenues$11.9M—
Collaboration Revenues$2.6M+67.0%

FAQ

When did Cytokinetics report Q1 2026 earnings?
Cytokinetics (CYTK) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Cytokinetics's Q1 2026 revenue and EPS?
Cytokinetics reported revenue of $19.4M and eps of $-1.67 for Q1 2026.
Did Cytokinetics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.5M by $10.8M. EPS beat the consensus estimate of $-1.67 by $0.00.
How did Cytokinetics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1125.8% from $1.6M a year earlier and eps declined 22.8% from $-1.36.
Where can I find Cytokinetics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206360) and the 10-Q periodic report (0001193125-26-206364) directly on SEC EDGAR. The filing index links above go to sec.gov.